A D Genazzani1, K Shefer2, D Della Casa2, A Prati2, A Napolitano2, A Manzo2, G Despini2, T Simoncini3. 1. Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. algen@unimo.it. 2. Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100, Modena, Italy. 3. Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.
Abstract
PURPOSE: To evaluate the efficacy of alpha-lipoic acid (ALA) administration on hormonal and metabolic parameters of obese PCOS patients. METHODS: A group of 32 obese PCOS patients were selected after informed consent. 20 patients referred to have first grade relatives with diabetes type I or II. Hormonal and metabolic parameters as well as OGTT were evaluated before and after 12 weeks of ALA integrative administration (400 mg per os every day). RESULTS: ALA administration significantly decreased insulin, glucose, BMI and HOMA index. Hyperinsulinemia and insulin response to OGTT decreased both as maximal response (Δmax) and as AUC. PCOS with diabetes relatives showed the decrease also of triglyceride and GOT. Interestingly in all PCOS no changes occurred on all hormonal parameters involved in reproduction such as LH, FSH, and androstenedione. CONCLUSIONS: ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes.
PURPOSE: To evaluate the efficacy of alpha-lipoic acid (ALA) administration on hormonal and metabolic parameters of obese PCOSpatients. METHODS: A group of 32 obese PCOSpatients were selected after informed consent. 20 patients referred to have first grade relatives with diabetes type I or II. Hormonal and metabolic parameters as well as OGTT were evaluated before and after 12 weeks of ALA integrative administration (400 mg per os every day). RESULTS:ALA administration significantly decreased insulin, glucose, BMI and HOMA index. Hyperinsulinemia and insulin response to OGTT decreased both as maximal response (Δmax) and as AUC. PCOS with diabetes relatives showed the decrease also of triglyceride and GOT. Interestingly in all PCOS no changes occurred on all hormonal parameters involved in reproduction such asLH, FSH, and androstenedione. CONCLUSIONS:ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOSpatients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes.
Authors: Richard M Thomas; Cheryl A Nechamen; Joseph E Mazurkiewicz; Alfredo Ulloa-Aguirre; James A Dias Journal: Endocrinology Date: 2011-02-01 Impact factor: 4.736
Authors: Jean-Patrice Baillargeon; Evanthia Diamanti-Kandarakis; Richard E Ostlund; Teimuraz Apridonidze; Maria J Iuorno; John E Nestler Journal: Diabetes Care Date: 2006-02 Impact factor: 19.112
Authors: Bart C J M Fauser; Basil C Tarlatzis; Robert W Rebar; Richard S Legro; Adam H Balen; Roger Lobo; Enrico Carmina; Jeffrey Chang; Bulent O Yildiz; Joop S E Laven; Jacky Boivin; Felice Petraglia; C N Wijeyeratne; Robert J Norman; Andrea Dunaif; Stephen Franks; Robert A Wild; Daniel Dumesic; Kurt Barnhart Journal: Fertil Steril Date: 2011-12-06 Impact factor: 7.329
Authors: Ji Cheol Bae; Eun Jung Rhee; Won Young Lee; Se Eun Park; Cheol Young Park; Ki Won Oh; Sung Woo Park; Sun Woo Kim Journal: Diabetes Care Date: 2011-01-28 Impact factor: 19.112
Authors: D Romualdi; V Versace; V Tagliaferri; S De Cicco; V Immediata; R Apa; M Guido; A Lanzone Journal: J Endocrinol Invest Date: 2019-03-07 Impact factor: 4.256
Authors: Francesca Cirillo; Cecilia Catellani; Pietro Lazzeroni; Chiara Sartori; Alessia Nicoli; Sergio Amarri; Giovanni Battista La Sala; Maria Elisabeth Street Journal: Front Endocrinol (Lausanne) Date: 2019-12-13 Impact factor: 5.555
Authors: Mateusz Maciejczyk; Ewa Żebrowska; Miłosz Nesterowicz; Elżbieta Supruniuk; Barbara Choromańska; Adrian Chabowski; Małgorzata Żendzian-Piotrowska; Anna Zalewska Journal: J Inflamm Res Date: 2022-04-08
Authors: Antonio Aversa; Sandro La Vignera; Rocco Rago; Alessandra Gambineri; Rossella E Nappi; Aldo E Calogero; Alberto Ferlin Journal: Front Endocrinol (Lausanne) Date: 2020-08-11 Impact factor: 5.555